Prudential PLC Buys 41 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Prudential PLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 0.4% during the 4th quarter, reports. The fund owned 10,061 shares of the company’s stock after acquiring an additional 41 shares during the period. Prudential PLC’s holdings in IDEXX Laboratories were worth $5,584,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Valley National Advisers Inc. boosted its holdings in IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares during the last quarter. Geo Capital Gestora de Recursos Ltd bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $28,000. Covestor Ltd boosted its holdings in shares of IDEXX Laboratories by 71.8% during the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after buying an additional 28 shares in the last quarter. DSM Capital Partners LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $33,000. Finally, Venturi Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after buying an additional 43 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now owns 161 shares in the company, valued at approximately $87,068.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Down 0.1 %

NASDAQ IDXX traded down $0.33 on Friday, reaching $497.51. The company had a trading volume of 380,918 shares, compared to its average volume of 509,065. The stock has a market capitalization of $41.09 billion, a P/E ratio of 48.16, a P/E/G ratio of 4.06 and a beta of 1.33. The company’s fifty day moving average is $503.07 and its 200 day moving average is $526.46. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of a number of research analyst reports. cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Thursday. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Morgan Stanley cut their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Finally, Barclays lowered their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $580.38.

View Our Latest Report on IDEXX Laboratories

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with's FREE daily email newsletter.